MTNBNYSEPharmaceutical PreparationsFiscal year ends December 31
Matinas BioPharma Holdings, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$1.66−0.71 (-29.96%)
Close on Oct 19, 2026
- Market cap
- $10.63M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$24.44 (−93.64%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Split
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $10.63M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 5.91
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- -$6.69M
- EPS, diluted
- -$1.21
- Book value per share
- $0.28
- Diluted shares
- 6M
Fourteen years at a glance
Fiscal years 2012 to 2025 and trailing twelve months, USD
Revenue
–
Operating income
-$6.67M
Net income
-$6.69M
EPS, diluted
-$1.21
Free cash flow
–
Reported periodTrailing twelve months